Workflow
VYNE Therapeutics (VYNE) - 2025 Q1 - Quarterly Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware 45-3757789 (I.R.S. Employer Identification No.) 685 Route 202/206 N, Suite 301 Bridgewater, New Jersey 08807 FOR THE TRANSITION PERIOD FROM ___ TO ___. (Address of principal executive offices ...